TAF Switch in F3/4 CHB pt With Partial Response to NUC (ESTAB-AFPVR)
Status:
Unknown status
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
A total of 80 adult chronic hepatitis B patients with advanced liver fibrosis (including
fibrosis stage 3 and cirrhosis), who are currently on nucleot(s)ide analogs (except tenofovir
alafenamide) therapy with detectable HBV DNA after 52 weeks of therapy will switch prior NUCs
to TAF 25 mg/day for 96 weeks
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital